ESC 365 - Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: A patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials

ESC Professional Premium Access

Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: A patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials

Session: Obesity and diabetes: key role for risk factor management

Topic: Diabetes and the Heart

Speaker: Doctor F. Moura (Boston, US)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Filipe Moura

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

1 follower

2 more presentations in this session

Relationship of obesity to mortality in 47 399 patients from nationwide LIPIDOGRAM 2004-2015 cohort studies.

Speaker: Doctor T. Osadnik (Zabrze, PL)

Prevalence of diabetic nephropathy and subsequent cardiovascular outcomes: a nationwide study of 74,014 patients with type 2 diabetes

Speaker: Doctor S. Parveen (Copenhagen, DK)

Access the full session

Obesity and diabetes: key role for risk factor management

Speakers: Doctor F. Moura, Doctor T. Osadnik, Doctor S. Parveen

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources